Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
about
Induction of apoptosis of human primary osteoclasts treated with extracts from the medicinal plant Emblica officinalisEfficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine AGlycyrol suppresses collagen-induced arthritis by regulating autoimmune and inflammatory responsesOn the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosisCrosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatasesCalcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivoTranscriptional regulation of bone and joint remodeling by NFATThe calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-like-4.A cell permeable peptide inhibitor of NFAT inhibits macrophage cytokine expression and ameliorates experimental colitisGlucocorticosteroids: current and future directions.Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function.Influence of renal complications on the efficacy and adverse events of tacrolimus combination therapy in patients with systemic lupus erythematosus (SLE) during a maintenance phase: a single-centre, prospective study.Angiopoietin-Like-4, a Potential Target of Tacrolimus, Predicts Earlier Podocyte Injury in Minimal Change Disease.Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus.Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterolSuccessful Tocilizumab Therapy for Macrophage Activation Syndrome Associated with Adult-Onset Still's Disease: A Case-Based ReviewTargeting signaling pathways with small molecules to treat autoimmune disorders.Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.Advances in use of immunomodulatory agents--a rheumatology perspective.Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells.Successful treatment with tacrolimus in a case of the glucocorticoid-dependent recurrent cutaneous eosinophilic vasculitisEfficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study.Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study.Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study.In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function.Immunomodulatory and protective properties of tacrolimus in experimental scorpion envenomation.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Production of the immunosuppressant cyclosporin A by a new soil isolate, Aspergillus fumigatus, in submerged culture.Norisoboldine, an alkaloid from Radix linderae, inhibits NFAT activation and attenuates 2,4-dinitrofluorobenzene-induced dermatitis in mice.Tacrolimus down-regulates chemokine expressions on rheumatoid synovial fibroblasts: screening by a DNA microarray.Combination of nifedipine and subtherapeutic dose of cyclosporin additively suppresses mononuclear cells activation of patients with rheumatoid arthritis and normal individuals via Ca(2+) -calcineurin-nuclear factor of activated T cells pathway.Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis.Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus
P2860
Q21254649-790047D3-41C6-4722-8153-4705A8DECB5FQ27333280-79AFF386-1511-45DD-939C-C8BF057948F1Q28540896-98734B2F-6412-4B21-A144-220F265A8DDBQ33346257-CD8371E0-F35B-4C00-9FED-26993228BE63Q33636430-3D099A18-41FE-44B4-A3DE-DC1C780C0328Q33903361-15E41850-2978-436F-B22F-00917D4F0A31Q33998768-2242E5AE-93EA-4BDC-B09F-F88E0E97D4F7Q34105415-8CC6FA17-A299-4D64-B25F-67CA9D53D064Q34222209-B48C6436-620F-41D1-9748-13B5E4F502D7Q34903070-558ECC1E-64E7-4F14-B234-16E75FD8D951Q35077814-19DA9D54-444F-4FC6-AE13-248E4B06D766Q35677419-EEB9D190-55A4-49EB-8938-E331101726EAQ35767979-447682C8-DB02-40F9-B8E7-C4BF42479A06Q35782786-E1F1F61F-BF99-4FAC-97E8-32BAF3E24347Q37100075-2225D90C-C3E8-4F83-9874-379932A291D9Q37263772-BFB641E5-A822-48E9-8B2D-D85A91F186D1Q37755216-7AA0F64A-DAED-49AF-8353-DA4CE1C93B4FQ38274571-866C5C2E-C7C9-4D91-8318-C0E675D31E6AQ38431512-F1439964-B2DD-4540-8353-D6A12CC068E6Q39841617-5BB4BCD0-0D3E-4E56-877C-6130F62FA773Q40993278-90233216-676E-40A2-8422-77440FE751E1Q42458610-C0A2026A-2795-4245-913B-7998015C0E75Q43285119-FE2C1857-345C-4418-970E-FF745A300395Q46606723-08FA6494-E92C-4BB8-A0DB-A76B1A3436D4Q46771769-BA53A45C-051C-4533-B745-1530DBA32460Q46783898-24A368B3-9A41-4B6E-94D9-F1BE7325307FQ47442388-F7C6CD78-1241-4D54-8BC4-1C16E5F9C7B8Q50264644-99FDBA23-1850-4DAA-B380-BF0D685B22BBQ51697569-1A91D9E6-EF40-414E-B8C1-F48CF9E8A484Q53151859-4EF7EE93-6C7C-41E6-AB0C-34EF31F09587Q54320957-FAD767E0-5C8A-483B-8450-3BA1F66A27F8Q54571811-C49F6035-A690-442E-8AF9-A45C0033CFB2Q58204824-0C69E5BF-3DA3-4AAB-A708-57051DB5348F
P2860
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
@en
type
label
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
@en
prefLabel
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
@en
P1476
Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
@en
P2093
Kanako Kitahara
Shinichi Kawai
P304
P356
10.1097/BOR.0B013E328099AF80
P577
2007-05-01T00:00:00Z